GRI_0621



NAME OF DRUG : GRI_0621

ALSO KNOWN AS : GRI_0621

LABORATORY : GRIPharma

STATUS AND ADVANCEMENT

Type of drug : NKT I Inhibitor

Clinical trials advancement : Analysing Results Phase 2a

Estimated time to market : 112 months.

LABORATORY ABSTRACT ON THE DRUG

GRI-0621 is an NKT I inhibitor that has a well established safety profile from studies in over 1500 patients. GRI-0621 is being developed as a 505(b)(2) submission for NASH, ASH and orphan liver indications.

GRI-0621 is currently being evaluated in 60 patients in a Phase 2a clinical study, with data expected in 2016. The trial includes patients on a background of NASH, alcoholic steatohepatitis (ASH) and viral hepatitis.

Phase 2b studies in NASH patients with fibrosisand alcoholic liver disease are anticipated to start in late 2016 /early 2017.

 

RECENT NEWS ON GRI_0621

SOME PUBLICATIONS RELATED WITH GRI_0621

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH GRI_0621


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE